Therefore, a novel therapeutic approach involving the targeted inhibition of STAT3 combined with the restoration of aberrant immune escape mechanisms within the tumor microenvironment represents a promising strategy that has gained significant traction in ongoing clinical trials. This evidence concerns the gene STAT3 and neoplasm.